← Back to All US Stocks

Valneva SE (VALN) Fundamental Analysis & AI Grade 2026

VALN Nasdaq Biological Products, (No Diagnostic Substances) I0 CIK: 0001836564
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Valneva SE (VALN) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

VALN Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

VALN vs Healthcare Sector: How Valneva SE Compares

How Valneva SE compares to Healthcare sector averages

Net Margin
VALN 0.0%
vs
Sector Avg 12.0%
VALN Sector
ROE
VALN 0.0%
vs
Sector Avg 15.0%
VALN Sector
Current Ratio
VALN 0.0x
vs
Sector Avg 2.0x
VALN Sector
Debt/Equity
VALN 0.0x
vs
Sector Avg 0.6x
VALN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Valneva SE Stock Overvalued? VALN Valuation Analysis 2026

Based on fundamental analysis, Valneva SE has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Valneva SE Balance Sheet: VALN Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

VALN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

VALN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Valneva SE (CIK: 0001836564)

📋 Recent SEC Filings

Date Form Document Action
Nov 16, 2022 SC 13D tm2230677d1_sc13d.htm View →
Oct 7, 2022 SC 13G deeptrack-valn092922.htm View →
Jun 29, 2022 SC 13G sch13g_valneva1x.htm View →
Feb 10, 2022 SC 13G tm225846d1_sc13g.htm View →

Frequently Asked Questions about VALN

What is the AI rating for VALN?

Valneva SE (VALN) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are VALN's key strengths?

Claude: Analysis in progress.

What are the risks of investing in VALN?

Claude: Analysis in progress.

What is VALN's revenue and growth?

Valneva SE reported revenue of N/A.

Does VALN pay dividends?

Valneva SE does not currently pay dividends.

Where can I find VALN SEC filings?

Official SEC filings for Valneva SE (CIK: 0001836564) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is VALN's EPS?

Valneva SE has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is VALN's fundamental grade?

Based on our AI fundamental analysis in May 2026, Valneva SE has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is VALN stock overvalued or undervalued?

Valuation metrics for VALN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is VALN's AI grade for 2026?

Our dual AI analysis gives Valneva SE a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is VALN's free cash flow?

Valneva SE's operating cash flow is N/A, with capital expenditures of N/A.

How does VALN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI